(Q34083140)

30 July 2017

Masitinib in advanced gastrointestinal stromal tumor (GIST) after failure of imatinib: a randomized controlled open-label trial (English)

1 reference

gastrointestinal stromal tumor

30 July 2017

1 reference

1 reference

18

1 reference

30 July 2017

10

I Ray-Coquard

0 references

Axel Le Cesne

19

object named as

A Le Cesne

0 references

Jean-Yves Blay

2

object named as

J-Y Blay

0 references

Patrice Dubreuil

object named as

P Dubreuil

14

0 references

author name string

A Adenis

1

1 reference

30 July 2017

B Bui-Nguyen

3

1 reference

30 July 2017

O Bouché

4

1 reference

30 July 2017

F Bertucci

5

1 reference

30 July 2017

N Isambert

6

1 reference

30 July 2017

E Bompas

7

1 reference

30 July 2017

L Chaigneau

8

1 reference

30 July 2017

J Domont

9

1 reference

30 July 2017

A Blésius

11

1 reference

30 July 2017

B A Van Tine

12

1 reference

30 July 2017

V R Bulusu

13

1 reference

30 July 2017

C D Mansfield

15

1 reference

30 July 2017

Y Acin

16

1 reference

30 July 2017

A Moussy

17

1 reference

30 July 2017

25 July 2014

1 reference

30 July 2017

1 reference

30 July 2017

25

1 reference

30 July 2017

9

1 reference

30 July 2017

1762-1769

1 reference

Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure

30 July 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143095

Comprehensive analysis of kinase inhibitor selectivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143095

Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143095

Overall survival as the outcome for randomized clinical trials with effective subsequent therapies

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143095

Management of side effects associated with sunitinib therapy for patients with renal cell carcinoma

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143095

Practical management of tyrosine kinase inhibitor-associated side effects in GIST.

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143095

Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors: a meta-analysis of 1,640 patients

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143095

Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143095

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143095

Novel mode of action of c-kit tyrosine kinase inhibitors leading to NK cell-dependent antitumor effects

5 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4143095

Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.

5 July 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU237

Natural killer cell IFN-gamma levels predict long-term survival with imatinib mesylate therapy in gastrointestinal stromal tumor-bearing patients

21 January 2018

1 reference

Crossref

https://api.crossref.org/works/10.1093%2FANNONC%2FMDU237

21 January 2018

Identifiers

DOI

10.1093/ANNONC/MDU237

1 reference

30 July 2017

1 reference

30 July 2017

1 reference